Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of JNJ-81201887 in geographic atrophy secondary to age-related macular degeneration
CTR20251128Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of JNJ-81201887 in geographic atrophy (GA), age-related macular degeneration (AMD), sponsored by Janssen Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20251128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251128.